ArticleArthritis research & therapy2025
Cluster analysis reveals three clinical phenotypes of pulmonary artery hypertension associated with connective tissue diseases: insights into inflammation and immunity.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Factors Associated with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease and Clinical Outcomes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Current landscape for connective tissue disease associated-pulmonary arterial hypertension: a focus on right ventricular adaptation and failure.Future cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundInflammation and immune mechanisms play a crucial role in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), though they remain inadequately understood. This study aimed to identify specific clinical phenotypes in CTD-PAH using inflammatory and immune markers through hierarchical cluster analysis.
methodsWe conducted a single-center, retrospective cohort study of CTD-PAH patients from 2009 to 2024. Clinical variables, including neutrophil lymphocyte ratio (NLR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and complement C3 and C4, were analyzed to form clusters based on baseline characteristics, clinical outcomes, and treatment goals.
resultsAmong 184 patients (95.1% female; median age 40.42 years), three distinct clusters were identified: Cluster 1 (vasculopathic phenotype) exhibited lower inflammatory activity but worse hemodynamic outcomes; Cluster 2 (vasculitic phenotype) had higher inflammatory activity with favorable hemodynamics; Cluster 3 (mixed phenotype) showed active inflammation and poor hemodynamic status. Most vasculitic patients were classified as systemic lupus erythematosus-associated PAH (SLE-PAH), which had a shorter course and higher prevalence of autoantibodies. The vasculopathic and mixed phenotypes were common in scleroderma-related PAH (SSc-PAH), undifferentiated CTD- related PAH (UCTD-PAH), and mixed CTD- related PAH (MCTD-PAH), associated with poorer treatment outcomes and survival rate.
conclusionDistinct clinical phenotypes in CTD-PAH correlate with inflammatory activity and hemodynamic status, influencing treatment responses and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.